EGFR and neoplasm: As new-generation EGFR-TKIs (e.g. osimertinib) 6, 7 have been developed recently for patients who showed resistance to conventional EGFR-TKIs, frequent examination of the tumor susceptibility to EGFR-TKIs became very important.